Argenx SE
ARGX
Rang in aandelen
#448
argenx SE, a biotechnology company established in Amsterdam, the Netherlands,... argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
Aandeelprijs
$875.26
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$54.72B
Verandering (1 dag)
6.01%
Verandering (1 jaar)
4.85%
Land
NL
Handel Argenx SE (ARGX)
Categorie
Healthcare
Omzet van Argenx SE (ARGX)
Omzet in Jun 2026 TTM: $6.02B
Volgens de laatste financiële rapporten van Argenx SE bedraagt de huidige omzet van het bedrijf (TTM) $6.02B. In 2023 behaalde het bedrijf een omzet van $1.23B een stijging ten opzichte van de omzet in het jaar 2022, die $410.75M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Argenx SE van 2011 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $6.02B | 174.92% |
| 2024 | $2.19B | 78.60% |
| 2023 | $1.23B | 198.56% |
| 2022 | $410.75M | -17.40% |
| 2021 | $497.28M | 890.02% |
| 2020 | $50.23M | -42.94% |
| 2019 | $88.03M | 211.75% |
| 2018 | $28.24M | -46.13% |
| 2017 | $52.42M | 221.96% |
| 2016 | $16.28M | 100.12% |
| 2015 | $8.14M | 47.24% |
| 2014 | $5.53M | 8.69% |
| 2013 | $5.08M | 76.55% |
| 2012 | $2.88M | 52.57% |
| 2011 | $1.89M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | 109.66% |
US
|
|
| $2.23B | -63.00% |
US
|
|
| $15.74B | 161.48% |
AU
|
|
| - | - |
CH
|
|
| $10.11B | 67.92% |
BE
|
